PT2035369E - Compostos terapêuticos - Google Patents
Compostos terapêuticos Download PDFInfo
- Publication number
- PT2035369E PT2035369E PT77637569T PT07763756T PT2035369E PT 2035369 E PT2035369 E PT 2035369E PT 77637569 T PT77637569 T PT 77637569T PT 07763756 T PT07763756 T PT 07763756T PT 2035369 E PT2035369 E PT 2035369E
- Authority
- PT
- Portugal
- Prior art keywords
- therapeutic compounds
- therapeutic
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006903625A AU2006903625A0 (en) | 2006-07-05 | Therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2035369E true PT2035369E (pt) | 2014-09-30 |
Family
ID=38894142
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT14173039T PT2799427T (pt) | 2006-07-05 | 2007-07-05 | Compostos terapêuticos |
PT77637569T PT2035369E (pt) | 2006-07-05 | 2007-07-05 | Compostos terapêuticos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT14173039T PT2799427T (pt) | 2006-07-05 | 2007-07-05 | Compostos terapêuticos |
Country Status (20)
Country | Link |
---|---|
US (2) | US8765812B2 (pt) |
EP (2) | EP2035369B1 (pt) |
JP (1) | JP5337693B2 (pt) |
KR (3) | KR101565271B1 (pt) |
CN (1) | CN101600683B (pt) |
AU (1) | AU2007271734B2 (pt) |
CA (1) | CA2656851C (pt) |
CY (2) | CY1115681T1 (pt) |
DK (2) | DK2799427T3 (pt) |
ES (2) | ES2505318T3 (pt) |
HK (1) | HK1203925A1 (pt) |
HU (1) | HUE039815T2 (pt) |
LT (1) | LT2799427T (pt) |
MX (1) | MX352516B (pt) |
NZ (1) | NZ574028A (pt) |
PL (1) | PL2035369T3 (pt) |
PT (2) | PT2799427T (pt) |
SI (2) | SI2035369T1 (pt) |
WO (1) | WO2008003141A1 (pt) |
ZA (1) | ZA200900004B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2505318T3 (es) | 2006-07-05 | 2014-10-09 | Fibrotech Therapeutics Pty Ltd | Compuestos terapéuticos |
WO2008131481A1 (en) * | 2007-04-26 | 2008-11-06 | Fibrotech Therapeutics Pty Ltd | Treatment of mesangioproliferative diseases |
MX337320B (es) * | 2007-12-21 | 2016-01-06 | Fibrotech Therapeutics Pty Ltd | Análogos halogenados de agentes anti-fibroticos. |
WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
US9062076B2 (en) | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
ES2829620T3 (es) | 2010-11-24 | 2021-06-01 | Occurx Pty Ltd | Procedimientos de tratamiento de enfermedades oculares asociadas con inflamación y proliferación vascular |
WO2012176693A1 (ja) * | 2011-06-24 | 2012-12-27 | 東京応化工業株式会社 | 新規化合物 |
JP5797476B2 (ja) * | 2011-06-24 | 2015-10-21 | 株式会社ダイセル | 不飽和カルボン酸アミド組成物の製造方法 |
CN103987858A (zh) | 2011-11-22 | 2014-08-13 | 英特芒尼公司 | 诊断和治疗特发性肺纤维化的方法 |
AR091586A1 (es) * | 2012-06-28 | 2015-02-11 | Fujifilm Corp | Derivado de amida o su sal como inhibidor de la produccion de colageno |
GB201522186D0 (en) | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
MX2019009235A (es) * | 2017-02-03 | 2019-12-11 | Certa Therapeutics Pty Ltd | Compuestos antifibroticos. |
EP3662908A1 (en) * | 2018-12-04 | 2020-06-10 | Consejo Superior de Investigaciones Cientificas (CSIC) | Modulating compounds of kchip2 and its use for the treatment of cardiovascular pathologies |
GB201902419D0 (en) * | 2019-02-22 | 2019-04-10 | Singapore Health Serv Pte Ltd | Treatment of kidney injury |
CN109970593B (zh) * | 2019-03-14 | 2019-11-08 | 北京工商大学 | 一种燕麦提取物的提取方法及其提取物和应用 |
CN111714480A (zh) * | 2020-07-21 | 2020-09-29 | 天津贝猫科技有限公司 | 邻氨基苯甲酸衍生物在制备治疗癌症药物中的用途 |
US11905231B1 (en) * | 2023-01-31 | 2024-02-20 | Certa Therapeutics Pty Ltd | Solid forms, salts and polymorphs of anti-fibrotic compounds |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5640710B2 (pt) | 1973-01-18 | 1981-09-22 | ||
JPS5830302B2 (ja) | 1974-04-16 | 1983-06-28 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ |
GB1484413A (en) * | 1974-04-18 | 1977-09-01 | Kissei Pharmaceutical | Aromatic amidocarboxylic acid derivatives |
JPS5848545B2 (ja) | 1974-04-18 | 1983-10-28 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ |
JPS511440A (ja) | 1974-04-18 | 1976-01-08 | Kissei Pharmaceutical | Shinkihokozokukarubonsanjudotai no seizohoho |
JPS5855138B2 (ja) | 1975-12-31 | 1983-12-08 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | ホウコウゾクカルボンサンアミドユウドウタイノセイゾウホウホウ |
JPS6019738B2 (ja) | 1978-03-20 | 1985-05-17 | 久光製薬株式会社 | 新規なアントラニル酸誘導体 |
JPS5576852A (en) * | 1978-12-01 | 1980-06-10 | Hisamitsu Pharmaceut Co Inc | Novel derivative of anthranilic acid |
JPS5817186B2 (ja) | 1981-01-23 | 1983-04-05 | キツセイ薬品工業株式会社 | 新規芳香族カルボン酸誘導体の製造方法 |
US4587356A (en) | 1981-09-01 | 1986-05-06 | Kissei Pharmaceutical Co., Ltd. | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives |
JPS6019754A (ja) | 1983-07-14 | 1985-01-31 | Kissei Pharmaceut Co Ltd | 芳香族カルボン酸アミド誘導体の製造方法 |
JPS60152454A (ja) * | 1984-01-18 | 1985-08-10 | Terumo Corp | アミド誘導体およびこれを有効成分として含有する5−リポキシゲナ−ゼ作用阻害剤 |
DE3505609A1 (de) | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | Benzimidazolyl-pyridazinone |
JPS625966A (ja) | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | ベンズイミダゾ−ル誘導体 |
JPH0692353B2 (ja) | 1987-05-26 | 1994-11-16 | マルコ製薬株式会社 | 新規なアミノ安息香酸アミド誘導体およびその製造法 |
JPS6416755A (en) | 1987-06-23 | 1989-01-20 | Biogal Gyogyszergyar | Manufacture of n-(3',4'-dimethoxycinnamoyl)-aniline derivative |
JPH07116029B2 (ja) * | 1989-04-04 | 1995-12-13 | キッセイ薬品工業株式会社 | トラニラスト水溶液製剤 |
DK0468054T3 (da) * | 1990-02-08 | 1997-06-16 | Eisai Co Ltd | Benzensulfonamidderivat |
US5248825A (en) * | 1990-09-20 | 1993-09-28 | Merrell Dow Pharmaceuticals Inc. | Calcium uptake inhibitors |
US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
ES2118333T3 (es) * | 1993-12-09 | 1998-09-16 | Ono Pharmaceutical Co | Derivados del acido naftilacetico como agonistas y antagonistas de pgez. |
US5665737B1 (en) | 1994-10-12 | 1999-02-16 | Euro Celtique Sa | Substituted benzoxazoles |
KR100237962B1 (ko) | 1994-10-12 | 2000-02-01 | 그린 마틴 | 신규한 벤즈옥사졸 |
JPH08113567A (ja) | 1994-10-17 | 1996-05-07 | Sando Yakuhin Kk | フェニルエテニル誘導体及びこれを含有する5−リポキシゲナーゼ阻害剤 |
US6444694B1 (en) | 1995-06-06 | 2002-09-03 | Wyeth | Styryl benzimidazole derivatives |
JPH08337523A (ja) | 1995-06-14 | 1996-12-24 | Taiho Yakuhin Kogyo Kk | 血管新生阻害剤 |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
ES2151464T3 (es) | 1996-02-07 | 2002-12-16 | Lead Chem Co Ltd | Preparacion para aplicacion externa que comprende tranilast y procedimiento para producirla. |
CZ258598A3 (cs) | 1996-02-15 | 1998-11-11 | Kissei Pharmaceutical Co., Ltd. | Inhibitor neovaskularizace |
JPH09278653A (ja) | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
DE19624155A1 (de) | 1996-06-18 | 1998-01-08 | Hoechst Ag | Substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten |
JPH10206024A (ja) * | 1997-01-14 | 1998-08-07 | Toho Eng Kk | チェーンコンベヤ炉 |
JPH10259129A (ja) | 1997-01-16 | 1998-09-29 | Kissei Pharmaceut Co Ltd | 血管新生阻害剤 |
FR2759368B1 (fr) * | 1997-02-10 | 2001-06-01 | Galderma Rech Dermatologique | Composes biaromatiques, compositions les contenant et utilisations |
JPH10306024A (ja) * | 1997-03-07 | 1998-11-17 | Kissei Pharmaceut Co Ltd | 糸球体疾患の予防および治療剤 |
JPH10330254A (ja) | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | 翼状片の進行および術後の再発抑制剤 |
US6127392A (en) * | 1997-08-05 | 2000-10-03 | American Home Products Corporation | Anthranilic acid analogs |
JP3256513B2 (ja) | 1998-02-11 | 2002-02-12 | ファイザー製薬株式会社 | ベンゾイミダゾールシクロオキシゲナーゼ−2阻害剤 |
CA2353635A1 (en) | 1998-12-21 | 2000-06-29 | Takeda Chemical Industries, Ltd. | Anilide derivative, production and use thereof |
DE19935219A1 (de) * | 1999-07-27 | 2001-02-01 | Boehringer Ingelheim Pharma | Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
WO2001074810A2 (en) | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists |
JP5010089B2 (ja) | 2000-09-19 | 2012-08-29 | スピロジェン リミテッド | Cc−1065およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法 |
WO2002055454A2 (en) | 2001-01-10 | 2002-07-18 | Smithkline Beecham Corporation | Process and product |
GB2372986A (en) | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
JP2004523529A (ja) | 2001-01-23 | 2004-08-05 | イーライ・リリー・アンド・カンパニー | メラノコルチンレセプターアゴニスト |
DE60237512D1 (de) * | 2001-02-28 | 2010-10-14 | Univ Temple | N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen |
US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
JP4851671B2 (ja) * | 2001-10-11 | 2012-01-11 | ニチバン株式会社 | トラニラスト経皮吸収貼付剤およびその製造方法 |
AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
US6759428B2 (en) | 2001-12-04 | 2004-07-06 | Roche Palo Alto Llc | Indole nitriles |
CA2468544A1 (en) | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
AU2002360763A1 (en) * | 2001-12-19 | 2003-07-09 | Atherogenics, Inc. | Chalcone derivatives and their use to treat diseases |
JPWO2003055847A1 (ja) * | 2001-12-27 | 2005-05-12 | 大正製薬株式会社 | カルボン酸誘導体 |
JP2004075614A (ja) | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
US7351719B2 (en) * | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
DE10254872A1 (de) | 2002-11-25 | 2004-06-03 | Symrise Gmbh & Co. Kg | Anthranilsäureamide und deren Derivate als kosmetische und pharmazeutische Wirkstoffe |
WO2004096757A1 (en) | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
US7250444B2 (en) * | 2003-08-11 | 2007-07-31 | Pfizer Inc. | Pyrrole-based HMG-CoA reductase inhibitors |
GB0319126D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
WO2005030705A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
DE10346913A1 (de) * | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
US7592373B2 (en) * | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004030987A1 (de) * | 2004-06-26 | 2006-01-12 | Merck Patent Gmbh | Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide |
US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
CA2573223C (en) | 2004-08-06 | 2013-05-21 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compound |
CA2586156A1 (en) * | 2004-11-04 | 2006-05-18 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
CN101098687A (zh) * | 2004-11-17 | 2008-01-02 | 安吉奥根制药控股有限公司 | 调节b细胞功能的方法 |
EP1824812A4 (en) * | 2004-11-23 | 2009-10-28 | Merck & Co Inc | AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES |
ITMI20050261A1 (it) | 2005-02-21 | 2006-08-22 | Carlo Ghisalberti | Analoghi strutturali di avenatramidi loro uso in composizioni utili nel trattamento di disordini dermatologici |
US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
CA2602583A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
US8697742B2 (en) | 2005-03-30 | 2014-04-15 | Kabushiki Kaisha Yakult Honsha | BCRP/ABCG2 inhibitor |
ITMI20050674A1 (it) | 2005-04-15 | 2006-10-16 | Univ Degli Studi Milano | Uso di derivati ammidici come agenti modificatori del gusto composizioni aromatizzanti e prodotti che li contengono |
KR20080016859A (ko) * | 2005-05-16 | 2008-02-22 | 앤지오젠 파마슈티칼스 피티와이. 리미티드 | 통증의 치료를 위한 방법 및 조성물 |
WO2006134013A1 (en) | 2005-06-14 | 2006-12-21 | Symrise Gmbh & Co. Kg | Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching |
WO2007015744A1 (en) | 2005-07-21 | 2007-02-08 | Incyte Corporation | Disubstituted thienyl compounds and their use as pharmaceuticals |
WO2007062957A1 (en) * | 2005-11-30 | 2007-06-07 | Symrise Gmbh & Co. Kg | Mixtures comprising anthranilic acid amides and antidandruff agents as cosmetic and pharmaceutical compositions for alleviating itching |
KR101495611B1 (ko) | 2006-04-07 | 2015-02-25 | 메틸진 인코포레이티드 | 히스톤 데아세틸라아제의 억제제 |
US20070286892A1 (en) * | 2006-06-13 | 2007-12-13 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
ES2462925T3 (es) * | 2006-06-14 | 2014-05-26 | Symrise Ag | Compuestos con efecto antimicrobiano para el tratamiento de fetidez oral |
ES2505318T3 (es) | 2006-07-05 | 2014-10-09 | Fibrotech Therapeutics Pty Ltd | Compuestos terapéuticos |
WO2008003378A1 (de) | 2006-07-05 | 2008-01-10 | Merck Patent Gmbh | Sulfamat-benzothiophen-derivate |
KR100832747B1 (ko) | 2006-10-27 | 2008-05-27 | 한국화학연구원 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
WO2008057862A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
CA2668190A1 (en) | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8765802B2 (en) | 2007-06-12 | 2014-07-01 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
EP2030617A1 (en) | 2007-08-17 | 2009-03-04 | Sygnis Bioscience GmbH & Co. KG | Use of tranilast and derivatives thereof for the therapy of neurological conditions |
US20090170842A1 (en) | 2007-11-14 | 2009-07-02 | University Of Kansas | Brca1-based breast or ovarian cancer prevention agents and methods of use |
WO2009068557A1 (en) | 2007-11-28 | 2009-06-04 | Neurosearch A/S | Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators |
CA2709883A1 (en) | 2007-12-19 | 2009-06-25 | The Scripps Research Institute | Benzimidazoles and analogs as rho kinase inhibitors |
US20090163586A1 (en) | 2007-12-20 | 2009-06-25 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 205 |
MX337320B (es) | 2007-12-21 | 2016-01-06 | Fibrotech Therapeutics Pty Ltd | Análogos halogenados de agentes anti-fibroticos. |
EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
CN101423503A (zh) | 2008-12-04 | 2009-05-06 | 上海大学 | 2-(反式-2,3-二氢-2-芳基-1-氰基-3-甲氧羰基环丙烷)-1,3-苯并噻唑及其合成方法 |
CA2754890C (en) | 2009-03-13 | 2018-01-16 | Piet Herdewijn | Bicyclic heterocycles |
US9062076B2 (en) | 2009-10-22 | 2015-06-23 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
-
2007
- 2007-07-05 ES ES07763756.9T patent/ES2505318T3/es active Active
- 2007-07-05 WO PCT/AU2007/000934 patent/WO2008003141A1/en active Application Filing
- 2007-07-05 EP EP07763756.9A patent/EP2035369B1/en active Active
- 2007-07-05 PL PL07763756T patent/PL2035369T3/pl unknown
- 2007-07-05 CN CN2007800327011A patent/CN101600683B/zh active Active
- 2007-07-05 DK DK14173039.0T patent/DK2799427T3/en active
- 2007-07-05 AU AU2007271734A patent/AU2007271734B2/en active Active
- 2007-07-05 HU HUE14173039A patent/HUE039815T2/hu unknown
- 2007-07-05 JP JP2009516828A patent/JP5337693B2/ja active Active
- 2007-07-05 KR KR1020147019764A patent/KR101565271B1/ko active IP Right Grant
- 2007-07-05 KR KR1020157014578A patent/KR101704953B1/ko active IP Right Grant
- 2007-07-05 ES ES14173039.0T patent/ES2689484T3/es active Active
- 2007-07-05 US US12/309,010 patent/US8765812B2/en active Active
- 2007-07-05 KR KR1020097000882A patent/KR101454038B1/ko active IP Right Grant
- 2007-07-05 PT PT14173039T patent/PT2799427T/pt unknown
- 2007-07-05 CA CA2656851A patent/CA2656851C/en active Active
- 2007-07-05 SI SI200731520T patent/SI2035369T1/sl unknown
- 2007-07-05 MX MX2009000001A patent/MX352516B/es active IP Right Grant
- 2007-07-05 NZ NZ574028A patent/NZ574028A/en unknown
- 2007-07-05 SI SI200732056T patent/SI2799427T1/sl unknown
- 2007-07-05 LT LTEP14173039.0T patent/LT2799427T/lt unknown
- 2007-07-05 EP EP14173039.0A patent/EP2799427B1/en active Active
- 2007-07-05 PT PT77637569T patent/PT2035369E/pt unknown
- 2007-07-05 DK DK07763756.9T patent/DK2035369T3/da active
-
2009
- 2009-01-01 ZA ZA200900004A patent/ZA200900004B/xx unknown
-
2014
- 2014-06-27 US US14/317,602 patent/US9561201B2/en active Active
- 2014-09-24 CY CY20141100774T patent/CY1115681T1/el unknown
-
2015
- 2015-05-05 HK HK15104283.1A patent/HK1203925A1/xx unknown
-
2018
- 2018-10-02 CY CY181101014T patent/CY1121043T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0610680D0 (en) | Therapeutic compounds | |
IL193678A0 (en) | Therapeutic compounds | |
GB0603041D0 (en) | Therapeutic compounds | |
EP2211620A4 (en) | THERAPEUTIC COMPOUNDS | |
HK1203925A1 (en) | Therapeutic compounds | |
GB0606663D0 (en) | Therapeutic compounds | |
GB0716532D0 (en) | Therapeutic compounds | |
GB0813087D0 (en) | Therapeutic compounds | |
EP2164324A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0615809D0 (en) | Therapeutic compounds | |
GB0612971D0 (en) | Therapeutic compounds | |
EP2185568A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0625349D0 (en) | Therapeutic compounds | |
EP2079704A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0625345D0 (en) | Therapeutic compounds | |
GB0605573D0 (en) | Therapeutic Compounds | |
GB0603455D0 (en) | Therapeutic compounds | |
GB0702862D0 (en) | Therapeutic compounds | |
GB0608269D0 (en) | Therapeutic compounds | |
GB2439923B (en) | Therapeutic compounds | |
GB0708188D0 (en) | Therapeutic compounds | |
GB0610670D0 (en) | Therapeutic compounds | |
GB0619687D0 (en) | Therapeutic compounds | |
GB0604049D0 (en) | Therapeutic compounds | |
GB0611498D0 (en) | Therapeutic compounds |